



October 24, 2014

PerkinElmer Expands Collaboration with ASAN Medical Centre and Center for Bio-Imaging of New Drug Development in South Korea

Provides Scientific Instruments and Expertise for Advancements in Translational Biomedical Imaging Research

WHAT: [PerkinElmer, Inc.](#), a global leader focused on improving the health and safety of people and the environment, today announced the expansion of its collaboration with ASAN Medical Centre (AMC), and the Center for Bio-imaging of New Drug Development (C-BiND) in Seoul, South Korea.

WHEN: Ceremony: Friday, October 24, 2014, 09:30a.m.-10:10a.m.

WHERE: ASAN Medical Centre, East Wing 6th floor, Main conference room, 88 Olympic-ro, 43-gil, Songpa-gu, Seoul, South Korea

ABOUT THE ALLIANCE: Through this collaboration, PerkinElmer will provide in vivo and in vitro molecular imaging instruments, along with support and expertise, to C-BiND at AMC. This combination of state-of-the-art technology and scientific expertise will help scientists advance translational biomedical imaging research, research new compounds, and create new devices for pre-clinical use.

"Our collaboration with ASAN Medical Centre, which began in 2012, will assist with the advancement of translational medicine research, with a specific focus on oncology," said Brian Kim, President, Life Sciences & Technology, PerkinElmer. "By expanding this collaboration through the provision of molecular imaging technology and expertise, we will assist scientists with gaining insights that can lead to breakthrough research."

AMC currently uses several of PerkinElmer's instruments in its research, including: the Opal™ multiplex tissue staining assays, Nuance® FX multiplex biomarker imaging system, inForm® Image Analysis Software, IVIS® Spectrum in vivo imaging system, JANUS® library prep workstation, Operetta® high content imaging system, EnVision® Multilabel Plate Reader, UltraVIEW® VoX 3D live cell imaging system, Quantum™ FX microCT Imaging System, and LabChip® GX microfluidic system. PerkinElmer also currently provides technical expertise in cellular imaging, tissue and small animal imaging.

"We are pleased to expand our relationship with PerkinElmer and to leverage its innovative technologies and industry knowledge and experience in support of our research efforts for translational medicine," said Seong-Wook Park, M.D., Ph.D and President of ASAN Medical Centre. "We look forward to working with PerkinElmer as we aim to advance research related to pathology, companion diagnostics, image-guided surgery and in vivo imaging."

MORE: PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately \$2.2 billion in 2013, has about 7,600 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com. Follow us on Twitter [@PKILifeScience](https://twitter.com/PKILifeScience)

Media Contact:

Yun Young

Email: young.yun@perkinelmer.com

+82-070-4680-070; mobile: +82-010-7155-6774